trial

Examining tDCS Effect on Cannabis Use Disorder in Patients With Schizophrenia

NCTId NCT04871048
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Recruiting
Enrollment 110 (estimated)
Sponsored by Centre Hospitalier Universitaire de Saint Etienne
Primary completion 2029-12-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Recruiting
Enrollment
110 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2023-02-15
Primary completion
2029-12-31
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Transcranial direct current stimulation (tDCS) activeTranscranial direct current stimulation (tDCS) non active

Sponsors

Centre Hospitalier Universitaire de Saint EtienneLead Sponsor
Direction Générale de l'Offre de SoinsCollaborator

Investigators

1
Aurelia GAY, MDPrincipal Investigator

Sites

8 total
Bron, FranceClermont-Ferrand, FranceClermont-Ferrand, FranceDijon, FranceLa Tronche, FranceSaint-Cyr-au-Mont-d'Or, FranceSaint-Égrève, FranceSaint-Priest-en-Jarez, France

Facts & assertions

4 sourced
Enrollment
110
Phase
NA
Primary Completion Date
2029-12-31
Status
RECRUITING
relationships
The graph out of here
drug
Transcranial direct current stimulation (tDCS) active
drug
Transcranial direct current stimulation (tDCS) non active
drug
lead_sponsor
Centre Hospitalier Universitaire de Saint Etienne
company
collaborator
Direction Générale de l'Offre de Soins
company
indication
Schizophrenia
indication
Cannabis-Induced Disorder
indication
Schizophrenia
indication
investigator
Aurelia GAY, MD
person